Lakefront Biotherapeutics (LKFT) Interest Coverage Ratio (2016 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Interest Coverage Ratio of 464.99 for Q1 2026, up 128.53% year-over-year from 203.47 in Q1 2025, and up 88.09% quarter-over-quarter from 247.21 in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Interest Coverage Ratio for 11 consecutive years, with 464.99 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 128.53% year-over-year to 464.99; the TTM figure through Mar 2026 stood at 354.95 (up 209.68% YoY), while the FY2025 annual figure was 285.34, up 238.17% from the prior year.
- Interest Coverage Ratio improved to 464.99 in Q1 2026 per LKFT's latest filing, from 247.21 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 464.99 in Q1 2026 and bottomed at 0.16 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 169.76 across 5 years, with a median of 197.44 in 2025.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 48990.5% — and 2025, when it slumped 40.95%.
- Lakefront Biotherapeutics' Interest Coverage Ratio stood at 0.16 in 2022, then jumped by 48990.5% to 76.89 in 2023, then sank by 38.31% to 47.44 in 2024, then jumped by 421.11% to 247.21 in 2025, then soared by 88.09% to 464.99 in 2026.
- Business Quant data shows LKFT's Interest Coverage Ratio at 464.99 in Q1 2026, 247.21 in Q4 2025, and 197.44 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 464.99 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | 370.62 |
| Jun 30, 2025 | 97.59 |
| Mar 31, 2025 | 203.47 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | 241.79 |
| Jun 30, 2024 | 419.12 |
| Mar 31, 2024 | 130.44 |
| Dec 31, 2023 | -0.08 |
| Mar 31, 2023 | 16.82 |
| Dec 31, 2022 | 0.00 |
| Mar 31, 2022 | 5.03 |
| Mar 31, 2021 | 4.48 |
| Jun 30, 2020 | 36.27 |
| Mar 31, 2020 | 1.86 |
| Dec 31, 2019 | 1.39 |
| Sep 30, 2019 | -10.17 |
| Jun 30, 2019 | 30.14 |
| Mar 31, 2019 | 22.70 |